Literature DB >> 10878069

Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.

G J Hanna1, V A Johnson, D R Kuritzkes, D D Richman, J Martinez-Picado, L Sutton, J D Hazelwood, R T D'Aquila.   

Abstract

The performances of two methods of nucleotide sequencing were compared for the detection of drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase (RT) in viruses isolated from highly RT inhibitor-experienced individuals. Of 11,677 amino acids deduced from population PCR products by both cycle sequencing and sequencing by hybridization to high-density arrays of oligonucleotide probes, 97.4% were concordant by both methods, 0.8% were discordant, and 1.7% had an ambiguous determination by at least one method. A higher rate of discordance (3.9%) was observed among RT inhibitor resistance-associated codons. In 45% of the isolates, RT codon 67 was deduced as the wild-type Asp by hybridization sequencing but as the zidovudine resistance-associated Asn by cycle sequencing. In other resistance-associated codon discordances, cycle sequencing also more commonly called a known resistance-associated amino acid than hybridization sequencing did. The nucleotide sequence in the vicinity of several codons with discordant calls influenced population-based hybridization sequencing. For isolates evaluated by additional sequencing of molecular clones of PCR products by both methods, the discordance between methods was less frequent (0.4% of all 5,994 amino acids and 0 of 494 drug resistance-associated codons). At positions which were discordant or ambiguous in the population sequences, the results of sequencing of clones by both methods were usually in agreement with the population cycle sequencing result. In summary, most RT codons were highly concordant by both methods of population-based sequencing, with discordances due in large part to genetic mixtures within or adjacent to discordant codons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878069      PMCID: PMC87006     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays.

Authors:  M J Kozal; N Shah; N Shen; R Yang; R Fucini; T C Merigan; D D Richman; D Morris; E Hubbell; M Chee; T R Gingeras
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

2.  Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Authors:  M D Hughes; V A Johnson; M S Hirsch; J W Bremer; T Elbeik; A Erice; D R Kuritzkes; W A Scott; S A Spector; N Basgoz; M A Fischl; R T D'Aquila
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

Review 3.  Viral dynamics of HIV: implications for drug development and therapeutic strategies.

Authors:  D V Havlir; D D Richman
Journal:  Ann Intern Med       Date:  1996-06-01       Impact factor: 25.391

4.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

5.  Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing.

Authors:  J Martinez-Picado; L Sutton; M P De Pasquale; A V Savara; R T D'Aquila
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

6.  Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.

Authors:  G J Hanna; V A Johnson; D R Kuritzkes; D D Richman; A J Brown; A V Savara; J D Hazelwood; R T D'Aquila
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

7.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

8.  Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.

Authors:  R T D'Aquila; M D Hughes; V A Johnson; M A Fischl; J P Sommadossi; S H Liou; J Timpone; M Myers; N Basgoz; M Niu; M S Hirsch
Journal:  Ann Intern Med       Date:  1996-06-15       Impact factor: 25.391

9.  Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

Authors:  R W Shafer; M J Kozal; M A Winters; A K Iversen; D A Katzenstein; M V Ragni; W A Meyer; P Gupta; S Rasheed; R Coombs
Journal:  J Infect Dis       Date:  1994-04       Impact factor: 5.226

Review 10.  Using oligonucleotide probe arrays to access genetic diversity.

Authors:  R J Lipshutz; D Morris; M Chee; E Hubbell; M J Kozal; N Shah; N Shen; R Yang; S P Fodor
Journal:  Biotechniques       Date:  1995-09       Impact factor: 1.993

View more
  9 in total

1.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

Review 2.  Overview of Next-Generation Sequencing Technologies.

Authors:  Barton E Slatko; Andrew F Gardner; Frederick M Ausubel
Journal:  Curr Protoc Mol Biol       Date:  2018-04

3.  Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.

Authors:  Valentina Svicher; Tobias Sing; Maria Mercedes Santoro; Federica Forbici; Fátima Rodríguez-Barrios; Ada Bertoli; Niko Beerenwinkel; Maria Concetta Bellocchi; Federigo Gago; Antonella d'Arminio Monforte; Andrea Antinori; Thomas Lengauer; Francesca Ceccherini-Silberstein; Carlo Federico Perno
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 4.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

5.  High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

Authors:  R W Shafer; K Hertogs; A R Zolopa; A Warford; S Bloor; B J Betts; T C Merigan; R Harrigan; B A Larder
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Evaluation of the editing process in human immunodeficiency virus type 1 genotyping.

Authors:  Diana D Huang; Susan H Eshleman; Donald J Brambilla; Paul E Palumbo; James W Bremer
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

7.  Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays.

Authors:  R Gonzalez; B Masquelier; H Fleury; B Lacroix; A Troesch; G Vernet; J N Telles
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 9.  A role for arrays in clinical virology: fact or fiction?

Authors:  Jonathan P Clewley
Journal:  J Clin Virol       Date:  2004-01       Impact factor: 3.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.